The ESMO Congress 2024 is currently underway in Barcelona, serving as a global hub for the latest advancements in oncology. Researchers, healthcare professionals, and press representatives from around the world have gathered to discuss cutting-edge data and emerging hot topics in cancer care. This year, some of the most compelling findings offer new hope for individuals impacted by breast cancer, especially those dealing with more aggressive forms of the disease.
KEYTRUDA’s Role in Triple-Negative Breast Cancer (TNBC)
A key highlight from the congress is the focus on treatments for aggressive cancers like triple-negative breast cancer (TNBC). KEYTRUDA, a prescription immunotherapy, is showing proven results when used alongside chemotherapy for TNBC patients with stage II and III disease. This marks an important step forward in reducing the risk of cancer returning. Ongoing studies are crucial in understanding how therapies like immunotherapy can improve survival rates and quality of life for patients with TNBC and other breast cancer subtypes.
Breastfeeding After Breast Cancer
Another critical research question answered from the ESMO Congress 2024 involves the safety of breastfeeding after early stage breast cancer diagnosis and treatment, where a mastectomy was not required. Two international studies have provided the first evidence suggesting that breastfeeding does not increase the risk of cancer recurrence or the development of new breast cancers in women previously treated for the disease. This finding is significant, as it addresses a major concern for young survivors that had a lumpectomy and additional cancer treatment who wish to breastfeed their children. Knowing that breastfeeding is both feasible and safe after a diagnosis and treatment for breast cancer can greatly enhance the quality of life for early stage, pre-menopausal survivors, offering more choices in their post-treatment lives.
As the ESMO Congress 2024 continues, the global oncology community remains focused on advancing research, improving treatments, and ultimately improving outcomes for all those affected by breast cancer. These findings represent just a snapshot of the progress being made in research, with more developments on the horizon.
Stay tuned for more updates from Breast Cancer Canada as we continue to bring you the latest from ESMO Congress 2024.